Compound tirzepatide at week 7: what 15 pounds actually means

What did @maddy.brett actually say?

She's seven shots into a compounded tirzepatide protocol, injecting into her thigh, and reporting zero side effects, including no nausea. She says she's been holding at a dose of "25" (presumably 2.5 mg, a common compounded unit), is now moving to "50" (likely 5 mg), and that this escalation was intentionally delayed by two weeks because she wasn't plateauing yet. She also lost "just under one pound" this week and wants to lose "at least two pounds a week." That's the full picture she's painting: slow, controlled weight loss on a low starting dose with a deliberate, patient titration strategy.

Worth noting: she mispronounces the drug name throughout, calling it "chisepatide" and "tirzepatize." Small thing, but it signals she may be working from limited pharmacological literacy, which matters when the rest of her advice gets more specific.

Does the science back this up?

The broad strokes of her experience are consistent with what clinical data shows. Tirzepatide, the dual GIP/GLP-1 receptor agonist studied in the SURMOUNT trials, does produce meaningful weight loss, and slower titration is genuinely associated with better GI tolerability. Her thigh injection site preference also has some logic behind it.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on 15 mg tirzepatide lost an average of 20.9% body weight over 72 weeks. That's the branded Mounjaro/Zepbound data. Her compounded version is a different product. The FDA has stated that compounded tirzepatide is not the same as FDA-approved tirzepatide, and there is no clinical trial data specifically on compounded formulations. Her results and side effect profile may or may not mirror what trials showed.

On the thigh-versus-abdomen question: a 2023 pharmacokinetic review in Diabetes, Obesity and Metabolism (Danne et al.) noted that injection site can influence absorption rate, though clinical significance for GLP-1 class drugs remains debated. The nausea-from-abdomen claim is widely repeated online but is not robustly established in the literature for tirzepatide specifically.

What did they get wrong (or right)?

She actually got the titration logic right, and that deserves credit. Holding at a lower dose until she genuinely plateaued rather than rushing to escalate is consistent with clinical guidance. The prescribing information for branded tirzepatide recommends slow titration precisely to reduce GI side effects, and patient-driven pacing with provider oversight is a reasonable real-world adaptation.

What she got wrong, or at least oversimplified: the claim that injecting in the thigh prevents nausea while the abdomen causes it is not well-supported evidence. Nausea from tirzepatide is primarily driven by the drug's mechanism of action at the GI level, not where it's injected. Telling 7,800 viewers that the abdomen site causes nausea could lead people to avoid a perfectly valid injection site for no evidence-based reason.

Her two-pounds-per-week target also deserves scrutiny. That's an aggressive goal. Standard clinical guidance from the American Society for Metabolic and Bariatric Surgery suggests 0.5 to 1 kg per week as a reasonable, sustainable rate. Chasing two pounds weekly can encourage dose-pushing behavior that increases side effect risk.

What should you actually know?

Compounded tirzepatide is not FDA-approved tirzepatide. Full stop. The FDA issued guidance in 2024 clarifying this distinction, and the agency has raised concerns about quality control variability in compounded GLP-1 products. That doesn't mean compounded versions are ineffective, but it means you cannot assume the same purity, potency, or safety profile as the brand-name drug studied in trials.

On dosing: the numbers she mentions, 25 and 50, likely refer to units drawn from a vial, not milligrams directly. Compounded tirzepatide vials vary in concentration by pharmacy. Without knowing the concentration, those numbers mean nothing to a viewer trying to compare their own protocol. This is exactly the kind of contextless dosing talk that can lead to dangerous self-titration by followers who think they're getting a benchmark.

If you're on any form of tirzepatide, compounded or branded, titration decisions should happen with a licensed prescriber, not based on when a creator's weight loss plateaus on TikTok.

• Injection site preference is personal and logistical, not a clinical nausea-prevention strategy.
• No side effects at week seven is genuinely good news, but GI effects can emerge at higher doses, so it's not a predictor of smooth sailing ahead.
• Compounded does not equal counterfeit, but it also does not equal equivalent. Know the difference.